Last updated July 7th, 2026. This is a fast-moving story, and details below may change before the hearing concludes on or before July 15, 2026.
After years of scientific review, legal challenges, and regulatory delays, the federal marijuana rescheduling process has reached one of its most significant milestones.
The Drug Enforcement Administration (DEA) began a formal administrative hearing on June 29, 2026, to consider whether marijuana more broadly should move from Schedule I to Schedule III under the Controlled Substances Act. This hearing is separate from an April 2026 final order that already placed two narrower categories, FDA-approved marijuana drug products and state-licensed medical marijuana into Schedule III, a move that is itself being challenged in the U.S. Court of Appeals for the D.C. Circuit. The June hearing won’t immediately change state cannabis laws, but its outcome could affect medical cannabis research, patient access, and the business landscape nationwide.
Here’s what we know so far, and why it matters.
How We Got Here
The current rescheduling effort began after the U.S. Department of Health and Human Services (HHS), supported by the Food and Drug Administration (FDA), concluded that cannabis has a currently accepted medical use and recommended moving it from Schedule I to Schedule III.
After delays through 2024 and 2025, President Trump issued a December 2025 executive order directing the Attorney General to expedite the process. In April 2026, the Acting Attorney General issued a final order immediately placing FDA-approved marijuana drug products and state-licensed medical marijuana into Schedule III, and separately opened a new, expedited hearing to consider broader rescheduling of marijuana as a whole. That hearing is now underway before an Administrative Law Judge, while the April order itself faces pending legal challenges.
The hearing will weigh scientific evidence, medical data, and legal argument before a recommendation goes to DEA leadership for a final decision.
What Is Actually Being Decided?
Despite many headlines, this hearing is not about legalizing marijuana nationwide.
The question is narrower: whether marijuana that hasn’t already been moved, meaning marijuana outside an FDA-approved drug product or a state medical license, still belongs in Schedule I, a category reserved for substances with no accepted medical use, or whether the evidence now supports Schedule III.
A Schedule III designation would acknowledge a recognized medical use while keeping marijuana under federal regulation.
What Could Schedule III Change?
If the broader rescheduling is approved, possible impacts include:
- Expanded opportunities for medical and scientific research.
- Reduced federal tax exposure under IRS Section 280E, a question already being tested in the courts for FDA-approved and state-licensed medical marijuana businesses following the April 2026 order (at least one company is currently suing the IRS over 280E treatment), and a possible future outcome for the broader industry if this hearing leads to full rescheduling. This is not yet a settled or guaranteed result.
- Greater alignment between federal science and existing state medical cannabis programs.
- Improved opportunities for pharmaceutical and clinical research.
It’s equally important to understand what rescheduling would not change: it would not automatically legalize recreational cannabis federally, eliminate state licensing requirements, or remove the complex regulations that already govern cannabis businesses.
What Has Happened During the Hearing?
Early testimony has focused on the FDA’s scientific review supporting a currently accepted medical use.
Opponents argue the evidence falls short of the legal standard under the Controlled Substances Act; supporters argue the scientific record supports rescheduling. DEA selected seven hearing participants, all opposed to rescheduling, and did not select pro-rescheduling groups, including NORML, to take part. NORML has since asked DEA in writing to reconsider that decision, and some advocates and observers have raised concerns about the resulting imbalance in whose evidence and cross-examination shape the hearing record.
As with most administrative proceedings of this size, expect additional testimony, a recommendation, and likely further legal challenges before there’s a final outcome.
Why This Matters to the Cannabis Industry
For cannabis operators, rescheduling is more than a regulatory headline. It could change how medical cannabis businesses operate financially, how researchers study cannabis, and how federal agencies approach the industry going forward.
The hearing itself is a sign that federal regulators are re-examining marijuana using current scientific evidence rather than older assumptions, though how the hearing resolves and on what timeline, remains genuinely uncertain.
What This Means for Patients, Providers, and the Future of Cannabis
Whatever the DEA ultimately decides, the medical cannabis industry continues to mature, and the need for well-informed, well-trained professionals in the space continues to grow.
As the process continues, expect plenty of headlines, opinion, and speculation. Our aim is to help patients and the cannabis community separate fact from fiction with clear, evidence-based information as federal policy evolves, whether the outcome is Schedule III or the status quo.
Have questions about what this means for you today, under current law? Book now or if you’d like more information first, call us at 412-730-3983.
Sources
- S. Department of Justice. Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III, Strengthening Medical Research While Maintaining Strict Federal Controls.
- S. Drug Enforcement Administration. Marijuana Rescheduling Regulatory Actions.
- Ohio State University Drug Enforcement and Policy Center. Federal Marijuana Rescheduling Timeline.
- Cannabis Business Times. DEA Comes Out Swinging in Cannabis Rescheduling Hearing.
This article is general information only, not legal or tax advice, and reflects the status of the hearing as of the date above. Rescheduling outcomes are not final, and businesses or patients should confirm how any of this applies to their specific situation with a qualified attorney or accountant before relying on it.
